FDA Approves Bayer's New Lung Cancer Treatment — Initial Results Appear Encouraging
FDA Approval for Hyrnuo: The FDA granted accelerated approval to Bayer AG's Hyrnuo (sevabertinib) for adults with advanced non-squamous non-small cell lung cancer (NSCLC) with HER2 mutations, following prior systemic therapy.
Companion Diagnostic Device: The Oncomine Dx Target Test was approved as a companion diagnostic to detect HER2 TKD activating mutations in NSCLC patients eligible for sevabertinib treatment.
Efficacy of Hyrnuo: In clinical studies, Hyrnuo showed a 71% objective response rate in patients with HER2 mutations who had prior systemic therapy, with a median duration of response of 9.2 months.
Full Approval for Imdelltra: The FDA also fully approved Amgen's Imdelltra (tarlatamab-dlle) for extensive stage small cell lung cancer, demonstrating a 40% reduction in death risk and extending median overall survival by over five months compared to standard chemotherapy.
Trade with 70% Backtested Accuracy
Analyst Views on AMGN
About AMGN
About the author
Dow Reaches 50,000 as Concerns Over AI Diminish
- Market Performance: The week was challenging for markets, but it concluded with a surge of optimism among investors.
- Dow 50K Discussion: The article focuses on the potential for the Dow Jones Industrial Average to reach the 50,000 mark, highlighting the factors that could contribute to this milestone.
- Investor Sentiment: Despite recent difficulties, there is a renewed sense of hope and positive sentiment in the market, suggesting a possible recovery.
- Future Outlook: Analysts are considering the implications of reaching the Dow 50K and what it could mean for the broader economy and investment strategies.
CVS Expands Biosimilar Access to Lower Drug Costs
- Biosimilar Introduction: CVS Health announced that starting April 1, 2026, it will add osteoporosis biosimilars Ospomyv and Stoboclo, along with generic teriparatide products Bonsity and Tymlos, to its major national commercial formularies, providing patients with more cost-effective treatment options.
- Significant Cost Savings: Ed DeVaney, President of CVS Caremark, stated that the company has generated $1.5 billion in gross savings for customers and members by replacing Humira with biosimilars, demonstrating the value of formulary tools in driving competition.
- High Transition Success Rate: CVS Caremark reported that 96% of its clients using Humira successfully transitioned to a biosimilar, indicating effective support and guidance provided during the medication switch process.
- Formulary Update Process: CVS Specialty proactively contacts prescribers and patients during formulary changes to explain updates and guide them through the transition, ensuring patients receive timely access to necessary treatments.
The Dow Exceeded 50,000: The Role of Caterpillar and Other Stocks in This Milestone.
Stock Market Surge: The stock market experienced a significant rebound, with the Dow Jones Industrial Average increasing by over 1,000 points.
Historic Milestone: This surge allowed the Dow to surpass the 50,000 mark for the first time in history.
The Dow Approaches 50,000, and It's Not Driven by Technology.
Market Performance: The stock market experienced a significant rebound, with the Dow Jones Industrial Average increasing by over 1,000 points.
Historic Milestone: This surge pushed the Dow above 50,000 for the first time in history.
Website Reports That Numerous Popular Brand-Name Medications, Including Fertility and Weight Loss Drugs, Are Available on TrumpRx
- Drug Listings: Many commonly prescribed brand-name drugs, including those for fertility and weight loss, are listed on TrumpRx.
- TrumpRx Overview: The platform appears to focus on providing information about various medications, particularly those associated with specific health conditions.
TRUMPRX.GOV WEBSITE GOES LIVE, REVEALS INFORMATION
Website Launch: A new website named "TRUMP RX GOV" has been launched, focusing on topics related to former President Donald Trump.
Content Features: The website showcases various content, likely including news, updates, and commentary on Trump's political activities and policies.
Dow Reaches 50,000 as Concerns Over AI Diminish
- Market Performance: The week was challenging for markets, but it concluded with a surge of optimism among investors.
- Dow 50K Discussion: The article focuses on the potential for the Dow Jones Industrial Average to reach the 50,000 mark, highlighting the factors that could contribute to this milestone.
- Investor Sentiment: Despite recent difficulties, there is a renewed sense of hope and positive sentiment in the market, suggesting a possible recovery.
- Future Outlook: Analysts are considering the implications of reaching the Dow 50K and what it could mean for the broader economy and investment strategies.
CVS Expands Biosimilar Access to Lower Drug Costs
- Biosimilar Introduction: CVS Health announced that starting April 1, 2026, it will add osteoporosis biosimilars Ospomyv and Stoboclo, along with generic teriparatide products Bonsity and Tymlos, to its major national commercial formularies, providing patients with more cost-effective treatment options.
- Significant Cost Savings: Ed DeVaney, President of CVS Caremark, stated that the company has generated $1.5 billion in gross savings for customers and members by replacing Humira with biosimilars, demonstrating the value of formulary tools in driving competition.
- High Transition Success Rate: CVS Caremark reported that 96% of its clients using Humira successfully transitioned to a biosimilar, indicating effective support and guidance provided during the medication switch process.
- Formulary Update Process: CVS Specialty proactively contacts prescribers and patients during formulary changes to explain updates and guide them through the transition, ensuring patients receive timely access to necessary treatments.
The Dow Exceeded 50,000: The Role of Caterpillar and Other Stocks in This Milestone.
Stock Market Surge: The stock market experienced a significant rebound, with the Dow Jones Industrial Average increasing by over 1,000 points.
Historic Milestone: This surge allowed the Dow to surpass the 50,000 mark for the first time in history.
The Dow Approaches 50,000, and It's Not Driven by Technology.
Market Performance: The stock market experienced a significant rebound, with the Dow Jones Industrial Average increasing by over 1,000 points.
Historic Milestone: This surge pushed the Dow above 50,000 for the first time in history.
Website Reports That Numerous Popular Brand-Name Medications, Including Fertility and Weight Loss Drugs, Are Available on TrumpRx
- Drug Listings: Many commonly prescribed brand-name drugs, including those for fertility and weight loss, are listed on TrumpRx.
- TrumpRx Overview: The platform appears to focus on providing information about various medications, particularly those associated with specific health conditions.
TRUMPRX.GOV WEBSITE GOES LIVE, REVEALS INFORMATION
Website Launch: A new website named "TRUMP RX GOV" has been launched, focusing on topics related to former President Donald Trump.
Content Features: The website showcases various content, likely including news, updates, and commentary on Trump's political activities and policies.
